Sign In
Buy KNSA
$60.94
-2.50 (-3.94%)
At Close: Jul 13, 2026
Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
09:01pm, Wednesday, 20'th Nov 2019
HAMILTON, Bermuda, Nov. 20, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference on.
Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
01:00pm, Wednesday, 20'th Nov 2019
Rilonacept is a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1α and IL-1β signaling. Kiniksa’s Breakthrough Therapy application was based on final data from an open-
Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
05:00pm, Saturday, 16'th Nov 2019
- Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores -- Tapering and discontinuation of corticosteroids without.
Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting
09:01pm, Tuesday, 12'th Nov 2019
- Mavrilimumab suppresses pathogenic immune responses in a validated in vivo model of medium and large vessel vasculitis - - Additional human ex vivo data support rationale for.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead
HAMILTON, Bermuda, May 13, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA ) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commerciali
